💉 Can Moderna Keep Up With Pfizer’s Juggernaut?

Things worsen for Peloton; Berkshire's record cash pile.

Hey Global Investor! Here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Friday’s Close) 4,697.53 +17.47 (0.37%)

NASDAQ (Friday’s Close) 15,971.59 +31.28 (0.20%)

FTSE 100 (4:30 PM IST) 7,302.35 -1.61 (0.02%)

NIFTY 50 (Today’s Close) 18,068.55 +151.75 (0.85%)

USDINR (Today’s Close) 74.06 (1 Year -1.25%)

🔥 Top Movers

BIGC +28.27%
CFLT +27.17%
GDYN +26.68%

TRHC -52.28%
BLUE -47.84%
EBS -37.07%

💉 Moderna: Left Behind?

Shares of Covid-19 vaccine maker Moderna (MRNA) tanked on Thursday and Friday after the company missed earnings estimates in Q3. It also expects to sell fewer vaccines in future quarters as against projections. The company is clearly losing the vaccine race to arch-rival Pfizer (PFE).  (Tweet This)

Hopes Dashed

Q2 results seem like a distant memory! Moderna shareholders were a happy bunch in August. The company was anticipating Covid vaccine sales worth $20B for the full year. It was looking to supply ~1B doses; there was talk of Advanced Purchase Agreements (APAs) being signed until 2023.

It seemed like Pfizer had some tough competition to deal with. A mere three months later, things have nosedived for Moderna, and how! The company not only missed earnings estimates by a huge margin in Q3 but also slashed revenue forecasts from the sale of the vaccine, its only cash cow.

Key Stats From Q3:

  • Revenue: $4.97B Vs. $6.21B expected
  • EPS: $7.70 Vs. $9.05 expected

Moderna also revised its full-year vaccine delivery target to ~800M from the earlier projection of ~1B doses. That meant slashing revenue expectations by a whopping $5B. Moderna now expects to earn ~$15B compared to the expected ~$20B. 2022 sales are expected to be ~$20B.

The company is grappling to fill vials and distribute them to meet unprecedented world demand. It has been having trouble ramping up infrastructure to fill up the dosage bottles and delivering them globally.

Moderna’s vaccine requires cold storage facilities that maintain temperatures of ~ minus 70 degrees Fahrenheit has meant additional logistical challenges. This is especially true when shipping the vaccine to low-income countries which lack the necessary cold storage infrastructure.

One Hit Wonder!

In comparison, Pfizer has issued a more bullish stance when it comes to vaccine deliveries. Along with its partner BioNTech, Pfizer expects vaccine sales this year of ~$36B and ~$29B in 2022. Both projections were higher than analyst expectations of $35.44B and $22.15B, respectively. Pfizer’s vaccine sales will be ~44% of the total revenue for this year.

Moderna’s contract manufacturer Lonza has been trying to ramp up manufacturing. The company has also enlisted Spanish contract drugmaker Rovi to build a new production facility in Granada. Through the Granada facility, the company hopes to cater to its European vaccine supplies.

Moderna’s vaccine has also been under scrutiny for the risk of heart inflammation, known as Myocarditis, which has been seen in vaccinated young males. The FDA has said that it will be early 2022 before assessing the vaccine for use in teenagers between 12-17 years of age.

Adding insult to injury, it turns out this Covid vaccine is Moderna’s only commercialized product. While vaccines for Covid-19 variants like Beta and Delta are being developed, they are still in development and will take time to be commercialized.

As Moderna was being buffeted from all sides – competition catapulting ahead, vaccine coming under scrutiny, and supply woes –  Pfizer has fired another salvo over the weekend, which may sink Moderna’s foundering ship even further. Pfizer said that its Covid-19 pill used with an HIV drug cuts the risk of hospitalization or death by 89% in high-risk adults who have been exposed to the virus. The news sent stocks of all vaccine makers, including Moderna, lower.

Moderna needs to figure out its game plan very quickly. Otherwise, it’ll soon risk being relegated to the annals of modern history!

Market Reaction
MRNA ended at $236.99, down 16.56%.

Company Snapshot 📈

MRNA $236.99 -47.03 (16.56%)

Analyst Ratings (17 Analysts) BUY 41%  HOLD 30%  SELL 29%

Newsworthy 📰

Nod: Twitter users say ‘yes’ to Musk’s proposal to sell 10% of his Tesla stock (TSLA -0.64%)

Panic: Peloton shares collapse as momentum for its at-home fitness equipment slows (PTON -35.28%)

New High: Supply chain problems crimp profit at Berkshire Hathaway; cash sets record (BRK.A +1.20%)

Later Today 🕒

  • PayPal Inc. Earnings (PYPL)
  • Lam Research Corporation Earnings (LRCX)
  • Roblox Corp. Earnings (RBLX)
  • The Trade Desk Inc. Earnings (TTD)
  • AMC Entertainment Holdings (AMC)
  • Trex Company Inc. Earnings (TREX)
  • Oak Street Health Inc. Earnings (OSH)
  • Five9 Inc. Earnings (FIVN)
  • US Foods Holding Corp. Earnings (USFD)
  • Coty Inc. Earnings (COTY)
  • Zynga Inc. Earnings (ZNGA)
  • Primerica Inc. Earnings (PRI)
  • Freshpet Inc. Earnings (FRPT)
  • Squarespace Inc. Earnings (SQSP)
  • Virgin Galactic Holdings Inc. Earnings (SPCE)
  • Tripadvisor Inc. Earnings (TRIP)

Today’s Market Terminology: Hedge

Hedging is a strategy or an attempt in reducing the risk of adverse price movement in one particular asset class

Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started